摘要
摘要
BACKGROUND: Depth of tumor response (DepOR) of individual patients, as visualized by waterfall plots, is a short-term endpoint that may represent a surrogate for survival-based outcomes such as progression-free survival (PFS) and overall survival (OS). We hypothesized that PFS/OS could be predicted from waterfall plots in randomized clinical trials (RCTs) using a novel machine-learning (ML) computational model. MATERIALS AND METHODS: A literature-based search was carried out for phase II/III RCTs testing noncytotoxic systemic therapy, which included waterfall plots with corresponding PFS/OS results. Studies were defined as positive or negative based on achievement of an a priori-stated primary endpoint. Trial data and images of waterfall plots were manually extracted and then processed through a semi-automatic extraction process. We developed the MAP-OUTCOMES (MAchine learning model to Predict PFS and OS OUTCOMES) model using regularized logistic regression. This model was applied to a training set comprising 70% of the data, and 30% was used for a test set. RESULTS: A total of 91 unique RCTs were identified, and 82 (93 trial pairs) retained for the ML analysis. Most of the trials were phase III (75%), with 67% using PFS as the primary endpoint and a mean sample size of 350 patients per arm. The most common tumor type was genitourinary (22%), and small-molecule targeted agents (27%) were the most frequent regimen. The model's performance achieved 71% accuracy [95% confidence interval (CI) 0.536-0.862, P = 0.18] with an area under the curve (AUC) of 65% (95% CI 0.333-0.938, P = 0.157) and area under the precision-recall curve (AUPRC) of 90% (95% CI 0.779-0.995, P = 0.171) in the 28 trials used for the test set. CONCLUSIONS: The MAP-OUTCOMES model demonstrated the feasibility of using ML to predict survival-based outcomes from waterfall plots, thus providing a potential tool for early trial evaluation. Improving the model's performance with more training data and creating independent datasets are necessary steps to assess its generalizability for prospective clinical applications.
KM 提取结果
0 个 Figure · 0 个 KM 面板